<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39453501</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1912</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Naunyn-Schmiedeberg's archives of pharmacology</Title><ISOAbbreviation>Naunyn Schmiedebergs Arch Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00210-024-03532-7</ELocationID><Abstract><AbstractText>Diabetes mellitus (DM) is a persistent condition characterized by high levels of glucose in the blood due to irregularities in the secretion of insulin, its action, or both. The disease was believed to be incurable until insulin was extracted, refined, and produced for sale. In DM, insulin delivery devices and insulin analogs have improved glycemic management even further. Sulfonylureas, biguanides, alpha-glucosidase inhibitors, and thiazolidinediones are examples of newer-generation medications having high efficacy in decreasing hyperglycemia as a result of scientific and technological advancements. Incretin mimetics, dual glucose-dependent insulinotropic polypeptide, GLP-1 agonists, PPARs, dipeptidyl peptidase-4 inhibitors, anti-CD3 mAbs, glucokinase activators, and glimins as targets have all performed well in recent clinical studies. Considerable focus was placed on free FA receptor 1 agonist, protein tyrosine phosphatase-1B inhibitors, and Sparc-related modular calcium-binding protein 1 which are still being studied. Theranostics, stem cell therapy, gene therapy, siRNA, and nanotechnology are some of the new therapeutic techniques. Traditional Chinese medicinal plants will also be discussed. This study seeks to present a comprehensive analysis of the latest research advancements, the emerging trends in medication therapy, and the utilization of delivery systems in treating DM. The objective is to provide valuable insights into the application of different pharmaceuticals in the field of diabetes mellitus treatment. Also, the therapeutic approach for diabetic patients infected with COVID-19 will be highlighted. Recent clinical and experimental studies evidence the Egyptian experience. Finally, as per the knowledge of the state of the art, our conclusion and future perspective will be declared.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asaad</LastName><ForeName>Gihan F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doghish</LastName><ForeName>Ahmed S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, 11651, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashad</LastName><ForeName>Ahmed A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Dakroury</LastName><ForeName>Walaa A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0002-8162-8515</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt. walaa.ahmed2@buc.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Naunyn Schmiedebergs Arch Pharmacol</MedlineTA><NlmUniqueID>0326264</NlmUniqueID><ISSNLinking>0028-1298</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Drug delivery</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">Insulin</Keyword><Keyword MajorTopicYN="N">Nanoparticle</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39453501</ArticleId><ArticleId IdType="doi">10.1007/s00210-024-03532-7</ArticleId><ArticleId IdType="pii">10.1007/s00210-024-03532-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdelsalam SS, Korashy HM, Zeidan A, Agouni A (2019) The role of protein tyrosine phosphatase (PTP)-1B in cardiovascular disease and its interplay with insulin resistance. Biomolecules 9:2863</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom9070286</ArticleId></ArticleIdList></Reference><Reference><Citation>Aflori M (2021) Smart nanomaterials for biomedical applications—a review. Nanomaterials 11:396</Citation><ArticleIdList><ArticleId IdType="pubmed">33557177</ArticleId><ArticleId IdType="pmc">7913901</ArticleId><ArticleId IdType="doi">10.3390/nano11020396</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar SA, Ashour NA, Sharaky M et al (2023) Diabetes mellitus: classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother 168:115734</Citation><ArticleIdList><ArticleId IdType="pubmed">37857245</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2023.115734</ArticleId></ArticleIdList></Reference><Reference><Citation>Arutyunyan IV, Fatkhudinov TK, Makarov AV et al (2020) Regenerative medicine of pancreatic islets. World J Gastroenterol 26:2948</Citation><ArticleIdList><ArticleId IdType="pubmed">32587441</ArticleId><ArticleId IdType="pmc">7304103</ArticleId><ArticleId IdType="doi">10.3748/wjg.v26.i22.2948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahman F, Greish K, Taurin S (2019) Nanotechnology in insulin delivery for management of diabetes. Pharm Nanotechnol 7:113–128. https://doi.org/10.2174/2211738507666190321110721</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/2211738507666190321110721</ArticleId><ArticleId IdType="pubmed">30907328</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbot M, Ceccato F, Scaroni C (2018) Diabetes mellitus secondary to Cushing’s disease. Front Endocrinol (Lausanne). 9:284</Citation><ArticleIdList><ArticleId IdType="pubmed">29915558</ArticleId><ArticleId IdType="pmc">5994748</ArticleId><ArticleId IdType="doi">10.3389/fendo.2018.00284</ArticleId></ArticleIdList></Reference><Reference><Citation>Barić A, Dobrivojević Radmilović M (2021) Microglia and bradykinin cross talk in poststroke cognitive impairment in diabetes. Am J Physiol Physiol 320:C613–C618</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00402.2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Barresi V, Musmeci C, Rinaldi A, Condorelli DF (2022) Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets. Int J Mol Sci 23:8875</Citation><ArticleIdList><ArticleId IdType="pubmed">36012138</ArticleId><ArticleId IdType="pmc">9408055</ArticleId><ArticleId IdType="doi">10.3390/ijms23168875</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton JC, Acton RT (2017) Diabetes in HFE hemochromatosis. J Diabetes Res 2017:9826930</Citation><ArticleIdList><ArticleId IdType="pubmed">28331855</ArticleId><ArticleId IdType="pmc">5346371</ArticleId><ArticleId IdType="doi">10.1155/2017/9826930</ArticleId></ArticleIdList></Reference><Reference><Citation>Basha SK, Muzammil MS, Dhandayuthabani R, Kumari VS (2021) Development of nanoemulsion of alginate/Aloe vera for oral delivery of insulin. Mater Today Proc 36:357–363</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matpr.2020.04.138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereda G (2022) Oral antidiabetic medications: technical notes. J Diabet Nephrop Diabetes Manag 2:1–10</Citation></Reference><Reference><Citation>Bhakta S, Tsukahara T (2020) Artificial RNA editing with ADAR for gene therapy. Curr Gene Ther 20:44–54</Citation><ArticleIdList><ArticleId IdType="pubmed">32416688</ArticleId><ArticleId IdType="doi">10.2174/1566523220666200516170137</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnefond A, Unnikrishnan R, Doria A et al (2023) Monogenic diabetes. Nat Rev Dis Prim 9:12</Citation><ArticleIdList><ArticleId IdType="pubmed">36894549</ArticleId><ArticleId IdType="doi">10.1038/s41572-023-00421-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldara R, Tomajer V, Monti P et al (2023) Allo beta cell transplantation: specific features, unanswered questions, and immunological challenge. Front Immunol 14:1323439</Citation><ArticleIdList><ArticleId IdType="pubmed">38077372</ArticleId><ArticleId IdType="pmc">10701551</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1323439</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbó R, Rodríguez E (2023) Relevance of sugar transport across the cell membrane. Int J Mol Sci 24:6085</Citation><ArticleIdList><ArticleId IdType="pubmed">37047055</ArticleId><ArticleId IdType="pmc">10094530</ArticleId><ArticleId IdType="doi">10.3390/ijms24076085</ArticleId></ArticleIdList></Reference><Reference><Citation>Carboni E, Carta AR, Carboni E (2020) Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses 140. https://doi.org/10.1016/J.MEHY.2020.109776</Citation></Reference><Reference><Citation>Caturano A, Nilo R, Nilo D et al (2024) Advances in nanomedicine for precision insulin delivery. Pharmaceuticals 17:945</Citation><ArticleIdList><ArticleId IdType="pubmed">39065795</ArticleId><ArticleId IdType="pmc">11279564</ArticleId><ArticleId IdType="doi">10.3390/ph17070945</ArticleId></ArticleIdList></Reference><Reference><Citation>Cefalu WT, Kaul S, Gerstein HC et al (2018) Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care 41:14–31. https://doi.org/10.2337/DCI17-0057</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/DCI17-0057</ArticleId><ArticleId IdType="pubmed">29263194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cernea S, Raz I (2020) Insulin therapy: future perspectives. Am J Ther 27:E121–E132. https://doi.org/10.1097/MJT.0000000000001076</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0000000000001076</ArticleId><ArticleId IdType="pubmed">31567147</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhury A, Duvoor C, Reddy Dendi VS et al (2017) Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 8:6</Citation><ArticleIdList><ArticleId IdType="pubmed">28167928</ArticleId><ArticleId IdType="doi">10.3389/fendo.2017.00006</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla R, Madhu S, Makkar B et al (2020) RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab 24:1–122. https://doi.org/10.4103/IJEM.IJEM_225_20</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/IJEM.IJEM_225_20</ArticleId><ArticleId IdType="pubmed">32699774</ArticleId><ArticleId IdType="pmc">7328526</ArticleId></ArticleIdList></Reference><Reference><Citation>Chellathurai MS, Yong CL, Sofian ZM et al (2023) Self-assembled chitosan-insulin oral nanoparticles—a critical perspective review. Int J Biol Macromol 243:125125</Citation><ArticleIdList><ArticleId IdType="pubmed">37263321</ArticleId><ArticleId IdType="doi">10.1016/j.ijbiomac.2023.125125</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zou Q, Chen Y et al (2020) Regulation of SPARC family proteins in disorders of the central nervous system. Brain Res Bull 163:178–189</Citation><ArticleIdList><ArticleId IdType="pubmed">32417569</ArticleId><ArticleId IdType="doi">10.1016/j.brainresbull.2020.05.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H-T, Xu X, Lim PS, Hung K-Y (2021) Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015. Diabetes Care 44:89–97</Citation><ArticleIdList><ArticleId IdType="pubmed">33203706</ArticleId><ArticleId IdType="doi">10.2337/dc20-1913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciochina M, Balaban DV, Manucu G et al (2022) The impact of pancreatic exocrine diseases on the β-cell and glucose metabolism—a review with currently available evidence. Biomolecules 12:618</Citation><ArticleIdList><ArticleId IdType="pubmed">35625546</ArticleId><ArticleId IdType="pmc">9139037</ArticleId><ArticleId IdType="doi">10.3390/biom12050618</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronell-Tovar A, Pardo JP, Rodríguez-Romero A et al (2024) Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs. FEBS Lett 598:1811</Citation><ArticleIdList><ArticleId IdType="pubmed">38724486</ArticleId><ArticleId IdType="doi">10.1002/1873-3468.14901</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawoud MHS, Mannaa IS, Abdel-Daim A, Sweed NM (2023) Integrating artificial intelligence with quality by design in the formulation of lecithin/chitosan nanoparticles of a poorly water-soluble drug. AAPS PharmSciTech 24:169</Citation><ArticleIdList><ArticleId IdType="pubmed">37552427</ArticleId><ArticleId IdType="doi">10.1208/s12249-023-02609-5</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leiva-Hidalgo A, Brugues E, De Leiva-Perez A (2020) The true banting and best story: the priority rule and the discovery of the antidiabetic hormone. Front Diabetes 29:84–102. https://doi.org/10.1159/000506561</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000506561</ArticleId></ArticleIdList></Reference><Reference><Citation>Defronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795. https://doi.org/10.2337/DB09-9028</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/DB09-9028</ArticleId><ArticleId IdType="pubmed">19336687</ArticleId><ArticleId IdType="pmc">2661582</ArticleId></ArticleIdList></Reference><Reference><Citation>Donner T (2000) Insulin – pharmacology, therapeutic regimens and principles of intensive insulin therapy. Endotext 13:1–11</Citation></Reference><Reference><Citation>El-Dakrouri WA, Ibrahim HK, Ghorab MK, Ghorab MM (2010) Enhancement of the intranasal delivery of insulin via a novel mucoadhesive Carbopol gel. J Pharm Pharmacol 62:866–872</Citation><ArticleIdList><ArticleId IdType="pubmed">20636874</ArticleId><ArticleId IdType="doi">10.1211/jpp.62.07.0007</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsayed A, Al Remawi M, Qinna N et al (2009) Formulation and characterization of an oily-based system for oral delivery of insulin. Eur J Pharm Biopharm 73:269–279</Citation><ArticleIdList><ArticleId IdType="pubmed">19508890</ArticleId><ArticleId IdType="doi">10.1016/j.ejpb.2009.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Faro Barros J, Sahraoui PF, Kalia YN, Lapteva M (2022) Devices for active targeted delivery: a way to control the rate and extent of drug administration. Target Drug Deliv 349–387. https://doi.org/10.1002/9783527827855.ch14</Citation></Reference><Reference><Citation>Feingold KR (2022) Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext [Internet]</Citation></Reference><Reference><Citation>Feng F, Zhou B, Zhou C-L et al (2024) Vitamin D, selenium, and antidiabetic drugs in the treatment of type 2 diabetes mellitus with Hashimoto’s thyroiditis. World J Diabetes 15:209</Citation><ArticleIdList><ArticleId IdType="pubmed">38464371</ArticleId><ArticleId IdType="pmc">10921160</ArticleId><ArticleId IdType="doi">10.4239/wjd.v15.i2.209</ArticleId></ArticleIdList></Reference><Reference><Citation>Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet (London, England) 392:2180–2193. https://doi.org/10.1016/S0140-6736(18)32260-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32260-8</ArticleId><ArticleId IdType="pubmed">30293770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallwitz B (2019) Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne) 10. https://doi.org/10.3389/FENDO.2019.00389</Citation></Reference><Reference><Citation>Gandhi M, Joshi PN (2020) Nanorobots for in vivo monitoring: the future of nano-implantable devices.Nanobiomater Eng Concepts Their Appl Biomed Diagn. Nanobiomater Eng 1:227–252</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-32-9840-8_12</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Shaw RJ (2017) AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell 66:789–800. https://doi.org/10.1016/J.MOLCEL.2017.05.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MOLCEL.2017.05.032</ArticleId><ArticleId IdType="pubmed">28622524</ArticleId><ArticleId IdType="pmc">5553560</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein HC, Rutty CJ (2021) Insulin therapy: the discovery that shaped a century. Can J Diabetes 45:798–803</Citation><ArticleIdList><ArticleId IdType="pubmed">34045148</ArticleId><ArticleId IdType="doi">10.1016/j.jcjd.2021.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheibi S, Singh T, da Cunha JPMCM et al (2020) Insulin/glucose-responsive cells derived from induced pluripotent stem cells: disease modeling and treatment of diabetes. Cells 9:2465</Citation><ArticleIdList><ArticleId IdType="pubmed">33198288</ArticleId><ArticleId IdType="pmc">7696367</ArticleId><ArticleId IdType="doi">10.3390/cells9112465</ArticleId></ArticleIdList></Reference><Reference><Citation>Grisch-Chan HM, Schwank G, Harding CO, Thöny B (2019) State-of-the-art 2019 on gene therapy for phenylketonuria. Hum Gene Ther 30:1274–1283. https://doi.org/10.1089/HUM.2019.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/HUM.2019.111</ArticleId><ArticleId IdType="pubmed">31364419</ArticleId><ArticleId IdType="pmc">6763965</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillamat-Prats R (2021) The role of MSC in wound healing, scarring and regeneration. Cells 10:1729</Citation><ArticleIdList><ArticleId IdType="pubmed">34359898</ArticleId><ArticleId IdType="pmc">8305394</ArticleId><ArticleId IdType="doi">10.3390/cells10071729</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Song C, Feng X et al (2020) Isolation and hypoglycemic effects of water extracts from mulberry leaves in Northeast China. Food Funct 11:3112–3125. https://doi.org/10.1039/D0FO00012D</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0FO00012D</ArticleId><ArticleId IdType="pubmed">32196541</ArticleId></ArticleIdList></Reference><Reference><Citation>Haq FU, Siraj A, Ameer MA et al (2021) Comparative review of drugs used in diabetes mellitus—new and old. J Diabetes Mellit 11:115–131</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/jdm.2021.114009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmingsen B, Sonne DP, Metzendorf M-I, Richter B (2016) Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane database Syst Rev 10. https://doi.org/10.1002/14651858.CD012151.PUB2</Citation></Reference><Reference><Citation>Holst JJ (2019) From the incretin concept and the discovery of GLP-1 to today’s diabetes therapy. Front Endocrinol (Lausanne) 10:. https://doi.org/10.3389/FENDO.2019.00260</Citation></Reference><Reference><Citation>Hövelmann U, Brøndsted L, Kristensen NR, et al (2020) 237-OR: insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes. Diabetes 69: https://doi.org/10.2337/db20-237-OR</Citation></Reference><Reference><Citation>Ismail L, Materwala H, Al Kaabi J (2021) Association of risk factors with type 2 diabetes: a systematic review. Comput Struct Biotechnol J 19:1759–1785</Citation><ArticleIdList><ArticleId IdType="pubmed">33897980</ArticleId><ArticleId IdType="pmc">8050730</ArticleId><ArticleId IdType="doi">10.1016/j.csbj.2021.03.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jash A, Ubeyitogullari A, Rizvi SSH (2021) Liposomes for oral delivery of protein and peptide-based therapeutics: challenges, formulation strategies, and advances. J Mater Chem B 9:4773–4792</Citation><ArticleIdList><ArticleId IdType="pubmed">34027542</ArticleId><ArticleId IdType="doi">10.1039/D1TB00126D</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez V, Bosch F (2024) Gene therapy for diabetes. Textb Diabetes 1144–1153. https://doi.org/10.1002/9781119697473.ch78</Citation></Reference><Reference><Citation>Johns EC, Denison FC, Norman JE, Reynolds RM (2018) Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab 29:743–754. https://doi.org/10.1016/J.TEM.2018.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.TEM.2018.09.004</ArticleId><ArticleId IdType="pubmed">30297319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandregula B, Narisepalli S, Chitkara D, Mittal A (2022) Exploration of lipid-based nanocarriers as drug delivery systems in diabetic foot ulcer. Mol Pharm 19:1977–1998</Citation><ArticleIdList><ArticleId IdType="pubmed">35481377</ArticleId><ArticleId IdType="doi">10.1021/acs.molpharmaceut.1c00970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur P, Kumar M, Parkash J, Prasad DN (2019) Oral hypoglycemic drugs: an overview. J Drug Deliv Ther 9:770–777</Citation><ArticleIdList><ArticleId IdType="doi">10.22270/jddt.v9i3-s.2815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur M, Mharazanye TX (2024) A review on use of nanoparticles in the treatment of diabetes mellitus. Int J Pharm Drug Des 4:1–14</Citation></Reference><Reference><Citation>Khursheed R, Singh SK, Wadhwa S et al (2019) Treatment strategies against diabetes: success so far and challenges ahead. Eur J Pharmacol 862:172625</Citation><ArticleIdList><ArticleId IdType="pubmed">31449807</ArticleId><ArticleId IdType="doi">10.1016/j.ejphar.2019.172625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisel MA, Kulik LN, Tsybovsky IS et al (2001) Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm 216:105–114</Citation><ArticleIdList><ArticleId IdType="pubmed">11274812</ArticleId><ArticleId IdType="doi">10.1016/S0378-5173(01)00579-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon S, Kim YC, Park JY et al (2020) The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care 43:948–955. https://doi.org/10.2337/DC19-0936</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/DC19-0936</ArticleId><ArticleId IdType="pubmed">32132005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H, Park S-Y, Choi CS (2022) Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J 46:15</Citation><ArticleIdList><ArticleId IdType="pubmed">34965646</ArticleId><ArticleId IdType="doi">10.4093/dmj.2021.0280</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xu X, Huang W, Qian H (2018) Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges. Med Res Rev 38:381–425</Citation><ArticleIdList><ArticleId IdType="pubmed">28328012</ArticleId><ArticleId IdType="doi">10.1002/med.21441</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wang C, Liu F et al (2020) Mulberry leaf polyphenols attenuated postprandial glucose absorption via inhibition of disaccharidases activity and glucose transport in Caco-2 cells. Food Funct 11:1835–1844. https://doi.org/10.1039/C9FO01345H</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9FO01345H</ArticleId><ArticleId IdType="pubmed">32064488</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lou N, Liu X et al (2024) Exploring new mechanisms of Imeglimin in diabetes treatment: amelioration of mitochondrial dysfunction. Biomed Pharmacother 175:116755</Citation><ArticleIdList><ArticleId IdType="pubmed">38772155</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2024.116755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin R, Brown F, James S et al (2021) Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus. Diabet Med 38:e14528</Citation><ArticleIdList><ArticleId IdType="pubmed">33496979</ArticleId><ArticleId IdType="doi">10.1111/dme.14528</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Shan X, Yu J et al (2020a) Recent advances in inhaled formulations and pulmonary insulin delivery systems. Curr Pharm Biotechnol 21:180–193</Citation><ArticleIdList><ArticleId IdType="pubmed">31612824</ArticleId><ArticleId IdType="doi">10.2174/1389201020666191011152248</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang L, Zhang Y et al (2020b) Dendrobium officinale polysaccharide ameliorates diabetic hepatic glucose metabolism via glucagon-mediated signaling pathways and modifying liver-glycogen structure. J Ethnopharmacol 248:. https://doi.org/10.1016/J.JEP.2019.112308</Citation></Reference><Reference><Citation>Luo P, Qiu L, Liu Y et al (2020) Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg 103:69–72. https://doi.org/10.4269/AJTMH.20-0375</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/AJTMH.20-0375</ArticleId><ArticleId IdType="pubmed">32446312</ArticleId><ArticleId IdType="pmc">7356425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv W, Wang X, Xu Q, Lu W (2020) Mechanisms and characteristics of sulfonylureas and glinides. Curr Top Med Chem 20:37–56</Citation><ArticleIdList><ArticleId IdType="pubmed">31884929</ArticleId><ArticleId IdType="doi">10.2174/1568026620666191224141617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z, Lim TM, Lim L-Y (2005) Pharmacological activity of peroral chitosan–insulin nanoparticles in diabetic rats. Int J Pharm 293:271–280</Citation><ArticleIdList><ArticleId IdType="pubmed">15778065</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2004.12.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazhar M, Zhu Y, Qin L (2023) The interplay of dietary fibers and intestinal microbiota affects type 2 diabetes by generating short-chain fatty acids. Foods 12:1023</Citation><ArticleIdList><ArticleId IdType="pubmed">36900540</ArticleId><ArticleId IdType="pmc">10001013</ArticleId><ArticleId IdType="doi">10.3390/foods12051023</ArticleId></ArticleIdList></Reference><Reference><Citation>McAdams BH, Rizvi AA (2016) An overview of insulin pumps and glucose sensors for the generalist. J Clin Med 5:1–5</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm5010005</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre HD, Catalano P, Zhang C et al (2019) Gestational diabetes mellitus. Nat Rev Dis Prim 5:1–19</Citation></Reference><Reference><Citation>Mignogna C, Maddaloni E, D’Onofrio L, Buzzetti R (2021) Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. Expert Opin Investig Drugs 30:1209–1219</Citation><ArticleIdList><ArticleId IdType="pubmed">34936848</ArticleId><ArticleId IdType="doi">10.1080/13543784.2022.2022119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajan D (2023) Historical view of diabetics mellitus: from ancient Egyptian polyuria to discovery of insulin. https://doi.org/10.56397/SSSH.2023.07.05</Citation></Reference><Reference><Citation>Mohammadpour F, Kamali H, Gholami L et al (2022) Solid lipid nanoparticles: a promising tool for insulin delivery. Expert Opin Drug Deliv 19:1577–1595</Citation><ArticleIdList><ArticleId IdType="pubmed">36287584</ArticleId><ArticleId IdType="doi">10.1080/17425247.2022.2138328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed SS, Muhammed AS, Muhammed AS (2021) New targets for drug therapy in type 2 diabetes mellitus. Al-Rafidain J Med Sci 1:42–48</Citation><ArticleIdList><ArticleId IdType="doi">10.54133/ajms.v1i.26</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan ES, Tai LJ, Pham NC et al (2019) Antisense inhibition of glucagon receptor by IONIS-GCGR Rx improves type 2 diabetes without increase in hepatic glycogen content in patients with type 2 diabetes on stable metformin therapy. Diabetes Care 42:585–593. https://doi.org/10.2337/DC18-1343</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/DC18-1343</ArticleId><ArticleId IdType="pubmed">30765435</ArticleId></ArticleIdList></Reference><Reference><Citation>Nespoux J, Vallon V (2018) SGLT2 inhibition and kidney protection. Clin Sci (Lond) 132:1329–1339. https://doi.org/10.1042/CS20171298</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20171298</ArticleId><ArticleId IdType="pubmed">29954951</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann UH, Ho JSS, Chen S et al (2017) Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes. Mol Metab 6:1161–1172. https://doi.org/10.1016/J.MOLMET.2017.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MOLMET.2017.06.012</ArticleId><ArticleId IdType="pubmed">29031717</ArticleId><ArticleId IdType="pmc">5641600</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura E, Kjeldsen T, Hubalek F et al (2020) 236-OR: molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing. Diabetes 69</Citation></Reference><Reference><Citation>Niu M, Lu Y, Hovgaard L, Wu W (2011) Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine 6:1155</Citation><ArticleIdList><ArticleId IdType="pubmed">21822379</ArticleId><ArticleId IdType="pmc">3148843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ode KL, Chan CL, Granados A et al (2019) Cystic fibrosis related diabetes: Medical management. J Cyst Fibros 18:S10–S18. https://doi.org/10.1016/j.jcf.2019.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2019.08.003</ArticleId><ArticleId IdType="pubmed">31679720</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen C, Lees EK, Grant L et al (2013) Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice. Diabetologia 56:2286–2296. https://doi.org/10.1007/S00125-013-2992-Z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00125-013-2992-Z</ArticleId><ArticleId IdType="pubmed">23832083</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai SA, Kshirsagar NA (2016) Pioglitazone utilization, efficacy &amp; safety in Indian type 2 diabetic patients: a systematic review &amp; comparison with European Medicines Agency Assessment Report. Indian J Med Res 144:672–681. https://doi.org/10.4103/IJMR.IJMR_650_15</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/IJMR.IJMR_650_15</ArticleId><ArticleId IdType="pubmed">28361819</ArticleId><ArticleId IdType="pmc">5393077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini S, Zamarian V, Sordi V (2022) Strategies to improve the safety of iPSC-derived β cells for β cell replacement in diabetes. Transpl Int 35:10575</Citation><ArticleIdList><ArticleId IdType="pubmed">36090777</ArticleId><ArticleId IdType="pmc">9448870</ArticleId><ArticleId IdType="doi">10.3389/ti.2022.10575</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S, Zhang M, He Y et al (2016) Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes. Future Med Chem 8:1239–1258. https://doi.org/10.4155/FMC-2016-0064</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/FMC-2016-0064</ArticleId><ArticleId IdType="pubmed">27357615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbani N, Thornalley PJ (2024) Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis of insulin resistance, beta-cell glucotoxicity, and diabetic vascular complications. Front Endocrinol (Lausanne) 14:1268308</Citation><ArticleIdList><ArticleId IdType="pubmed">38292764</ArticleId><ArticleId IdType="doi">10.3389/fendo.2023.1268308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai U, Kosuru R, Prakash S, et al (2019) Tetramethylpyrazine prevents diabetes by activating PI3K/Akt/GLUT-4 signalling in animal model of type-2 diabetes. Life Sci 236. https://doi.org/10.1016/J.LFS.2019.116836</Citation></Reference><Reference><Citation>Ramu M, Vishal SS, Gogia N (2022) Role of AMP-activated protein kinase and sirtuins as antiaging proteins. In: Anti-aging drug discovery on the basis of hallmarks of aging. Elsevier, pp 241–278</Citation></Reference><Reference><Citation>Refaie AF, Elbassiouny BL, Kloc M et al (2021) From mesenchymal stromal/stem cells to insulin-producing cells: immunological considerations. Front Immunol 12:690623</Citation><ArticleIdList><ArticleId IdType="pubmed">34248981</ArticleId><ArticleId IdType="pmc">8262452</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.690623</ArticleId></ArticleIdList></Reference><Reference><Citation>Rendell M (2019) Premix insulins in type 1 diabetes: the coming of degludec/aspart. Expert Opin Drug Metab Toxicol 15:341–348. https://doi.org/10.1080/17425255.2019.1585427</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425255.2019.1585427</ArticleId><ArticleId IdType="pubmed">30789066</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld E, Thornton PS (2023) Hypoglycemia in neonates, infants, and children. Endotext [Internet]</Citation></Reference><Reference><Citation>Roy P, Saha S, Chakraborty J (2021) Looking into the possibilities of cure of the type 2 diabetes mellitus by nanoparticle-based RNAi and CRISPR-Cas9 system: a review. J Drug Deliv Sci Technol 66:102830</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2021.102830</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbagh F, Muhamad II, Niazmand R et al (2022) Recent progress in polymeric non-invasive insulin delivery. Int J Biol Macromol 203:222–243</Citation><ArticleIdList><ArticleId IdType="pubmed">35101478</ArticleId><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.01.134</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi P, Petersohn I, Salpea P, et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843</Citation></Reference><Reference><Citation>Sahin I, Bakiner O, Demir T, et al (2024) Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review. Diabetes Ther 1–30</Citation></Reference><Reference><Citation>Saini V (2022) Islet-enriched microRNAs as biomarkers/regulators of beta cell function, survival and differentiation. University of Technology Sydney (Australia)</Citation></Reference><Reference><Citation>Sánchez-Alegría K, Bastián-Eugenio CE, Vaca L, Arias C (2021) Palmitic acid induces insulin resistance by a mechanism associated with energy metabolism and calcium entry in neuronal cells. FASEB J 35:e21712</Citation><ArticleIdList><ArticleId IdType="pubmed">34110637</ArticleId><ArticleId IdType="doi">10.1096/fj.202100243R</ArticleId></ArticleIdList></Reference><Reference><Citation>Santalices I, Vázquez-Vázquez C, Santander-Ortega MJ et al (2021) A nanoemulsion/micelles mixed nanosystem for the oral administration of hydrophobically modified insulin. Drug Deliv Transl Res 11:524–545</Citation><ArticleIdList><ArticleId IdType="pubmed">33575972</ArticleId><ArticleId IdType="pmc">7987602</ArticleId><ArticleId IdType="doi">10.1007/s13346-021-00920-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarangi M, Padhi S, Rath G (2024) Non-invasive delivery of Insulin for breaching hindrances against diabetes. Crit Rev Ther Drug Carr Syst 41:1</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevTherDrugCarrierSyst.2023048197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardu C, D’Onofrio N, Balestrieri ML et al (2020) Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care 43:1408–1415. https://doi.org/10.2337/DC20-0723</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/DC20-0723</ArticleId><ArticleId IdType="pubmed">32430456</ArticleId><ArticleId IdType="pmc">7305003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmento B, Martins S, Ribeiro A et al (2006) Development and comparison of different nanoparticulate polyelectrolyte complexes as insulin carriers. Int J Pept Res Ther 12:131–138</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10989-005-9010-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmento B, Martins S, Ferreira D, Souto EB (2007) Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine 2:743</Citation><ArticleIdList><ArticleId IdType="pubmed">18203440</ArticleId><ArticleId IdType="pmc">2676823</ArticleId></ArticleIdList></Reference><Reference><Citation>Seetharaman R, Pawar S, Advani M (2022) One hundred years since insulin discovery: an update on current and future perspectives for pharmacotherapy of diabetes mellitus. Br J Clin Pharmacol 88:1598–1612</Citation><ArticleIdList><ArticleId IdType="pubmed">34608666</ArticleId><ArticleId IdType="doi">10.1111/bcp.15100</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty SS, Halagali P, Johnson AP et al (2023) Oral insulin delivery: barriers, strategies, and formulation approaches: a comprehensive review. Int J Biol Macromol 242:125114</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2023.125114</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A-K, Jatwa R, Purohit A, Ram H (2017) Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes. J Asian Nat Prod Res 19:1036–1045</Citation><ArticleIdList><ArticleId IdType="pubmed">28351157</ArticleId><ArticleId IdType="doi">10.1080/10286020.2017.1307183</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RB, Sharma JP, Elkilany G et al (2023) Ancient history of medicine in India, with reference to cardiovascular diseases and diabetes. World Heart J 15:49–67</Citation></Reference><Reference><Citation>Singh G, Kumar R, DS D, et al (2024) Thiazolidinedione as a promising medicinal scaffold for the treatment of type 2 diabetes. Curr Diabetes Rev 20:89–109</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0115733998254798231005095627</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Zhi Z, Pickup JC (2014) Nanolayer encapsulation of insulin-chitosan complexes improves efficiency of oral insulin delivery. Int J Nanomedicine 9:2127</Citation><ArticleIdList><ArticleId IdType="pubmed">24833901</ArticleId><ArticleId IdType="pmc">4014370</ArticleId></ArticleIdList></Reference><Reference><Citation>Sora ND, Shashpal F, Bond EA, Jenkins AJ (2019) Insulin pumps: review of technological advancement in diabetes managemenT. Am J Med Sci 358:326–331. https://doi.org/10.1016/J.AMJMS.2019.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AMJMS.2019.08.008</ArticleId><ArticleId IdType="pubmed">31655714</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Luo Y, Hu S et al (2023) Advances in research on type 2 diabetes mellitus targets and therapeutic agents. Int J Mol Sci 24:13381</Citation><ArticleIdList><ArticleId IdType="pubmed">37686185</ArticleId><ArticleId IdType="pmc">10487533</ArticleId><ArticleId IdType="doi">10.3390/ijms241713381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun EW, De Fontgalland D, Rabbitt P et al (2017) Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine. Diabetes 66:2144–2149. https://doi.org/10.2337/DB17-0058</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/DB17-0058</ArticleId><ArticleId IdType="pubmed">28385801</ArticleId><ArticleId IdType="pmc">5860185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson B, Patil NG, Fok M et al (2022) The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opin Pharmacother 23:387–403</Citation><ArticleIdList><ArticleId IdType="pubmed">34758676</ArticleId><ArticleId IdType="doi">10.1080/14656566.2021.1999413</ArticleId></ArticleIdList></Reference><Reference><Citation>Waghode P, Quadir SS, Choudhary D et al (2024) Small interfering RNA (siRNA) as a potential gene silencing strategy for diabetes and associated complications: challenges and future perspectives. J Diabetes Metab Disord 23:365</Citation><ArticleIdList><ArticleId IdType="pubmed">38932822</ArticleId><ArticleId IdType="doi">10.1007/s40200-024-01405-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahab S, Khalid M, Alqarni MH et al (2023) Antihyperglycemic potential of Spondias mangifera fruits via inhibition of 11β-HSD type 1 enzyme: in silico and in vivo approach. J Clin Med 12:2152</Citation><ArticleIdList><ArticleId IdType="pubmed">36983154</ArticleId><ArticleId IdType="pmc">10051293</ArticleId><ArticleId IdType="doi">10.3390/jcm12062152</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczewska-Szewc K, Nowak W (2021) Photo-switchable sulfonylureas binding to ATP-sensitive potassium channel reveal the mechanism of light-controlled insulin release. J Phys Chem B 125:13111–13121</Citation><ArticleIdList><ArticleId IdType="pubmed">34825567</ArticleId><ArticleId IdType="pmc">8667036</ArticleId><ArticleId IdType="doi">10.1021/acs.jpcb.1c07292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Liu Q, Kang S-G et al (2021) Dietary bioactive ingredients modulating the cAMP signaling in diabetes treatment. Nutrients 13:3038</Citation><ArticleIdList><ArticleId IdType="pubmed">34578916</ArticleId><ArticleId IdType="pmc">8467569</ArticleId><ArticleId IdType="doi">10.3390/nu13093038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang N, Zhang W et al (2022) Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 7:48</Citation><ArticleIdList><ArticleId IdType="pubmed">35165272</ArticleId><ArticleId IdType="pmc">8844085</ArticleId><ArticleId IdType="doi">10.1038/s41392-022-00904-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner C, Marx N (2018) SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 61:2134–2139. https://doi.org/10.1007/S00125-018-4678-Z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00125-018-4678-Z</ArticleId><ArticleId IdType="pubmed">30132035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wayne CD, Benbetka C, Besner GE, Narayanan S (2024) Challenges of managing type 3c diabetes in the context of pancreatic resection, cancer and trauma. J Clin Med 13:2993</Citation><ArticleIdList><ArticleId IdType="pubmed">38792534</ArticleId><ArticleId IdType="pmc">11122338</ArticleId><ArticleId IdType="doi">10.3390/jcm13102993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Qi L, Lin H et al (2020) Pathological mechanisms in diabetes of the exocrine pancreas: what’s known and what’s to know. Front Physiol 11:570276</Citation><ArticleIdList><ArticleId IdType="pubmed">33250773</ArticleId><ArticleId IdType="pmc">7673428</ArticleId><ArticleId IdType="doi">10.3389/fphys.2020.570276</ArticleId></ArticleIdList></Reference><Reference><Citation>White J, Goldman J (2019) Biosimilar and follow-on insulin: the ins, outs, and interchangeability. J Pharm Technol 35:25–35. https://doi.org/10.1177/8755122518802268</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/8755122518802268</ArticleId><ArticleId IdType="pubmed">34861004</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zheng Y, Wu L et al (2018) Novel solid lipid nanoparticle with endosomal escape function for oral delivery of insulin. ACS Appl Mater Interfaces 10:9315–9324</Citation><ArticleIdList><ArticleId IdType="pubmed">29484890</ArticleId><ArticleId IdType="doi">10.1021/acsami.8b00507</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau M, Maclaren NK, Sperling MA (2021) Etiology and pathogenesis of diabetes mellitus in children and adolescents. Endotext [Internet]</Citation></Reference><Reference><Citation>Yu M, Benjamin MM, Srinivasan S et al (2018) Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev 130:113–130. https://doi.org/10.1016/J.ADDR.2018.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.ADDR.2018.07.009</ArticleId><ArticleId IdType="pubmed">30009885</ArticleId><ArticleId IdType="pmc">6843995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang L, Hao H, Liu J, et al (2017) Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr 9. https://doi.org/10.1186/S13098-017-0233-1</Citation></Reference><Reference><Citation>Zare F, Ataollahi E, Mardaneh P et al (2024) A combination of virtual screening, molecular dynamics simulation, MM/PBSA, ADMET, and DFT calculations to identify a potential DPP4 inhibitor. Sci Rep 14:7749</Citation><ArticleIdList><ArticleId IdType="pubmed">38565703</ArticleId><ArticleId IdType="pmc">10987597</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-58485-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Li J, Jiang W et al (2010) Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int J Pharm 393:213–219</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao R, Lu Z, Yang J, et al (2020) Drug delivery system in the treatment of diabetes mellitus. Front Bioeng Biotechnol 8. https://doi.org/10.3389/FBIOE.2020.00880</Citation></Reference><Reference><Citation>Zhao Z, Liu W (2020) Pancreatic cancer: a review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat 19:1533033820962117</Citation><ArticleIdList><ArticleId IdType="pubmed">33357065</ArticleId><ArticleId IdType="pmc">7768873</ArticleId><ArticleId IdType="doi">10.1177/1533033820962117</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>